These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 18507656)

  • 1. The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects.
    Kovarik JM; Slade A; Riviere GJ; Neddermann D; Maton S; Hunt TL; Schmouder RL
    Br J Clin Pharmacol; 2008 Aug; 66(2):199-206. PubMed ID: 18507656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects.
    Kovarik JM; Lu M; Riviere GJ; Barbet I; Maton S; Goldwater DR; Schmouder RL
    Eur J Clin Pharmacol; 2008 May; 64(5):457-63. PubMed ID: 18196225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mechanistic study to assess whether isoproterenol can reverse the negative chronotropic effect of fingolimod.
    Kovarik JM; Riviere GJ; Neddermann D; Maton S; Hunt TL; Schmouder RL
    J Clin Pharmacol; 2008 Mar; 48(3):303-10. PubMed ID: 18218783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects.
    Kovarik JM; Hartmann S; Bartlett M; Riviere GJ; Neddermann D; Wang Y; Port A; Schmouder RL
    Biopharm Drug Dispos; 2007 Mar; 28(2):97-104. PubMed ID: 17230596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ethnic sensitivity study of fingolimod in white and Asian subjects.
    Kovarik JM; Slade A; Voss B; Schmidli H; Riviere GJ; Picard F; Sugita Y; Kawai R; Mee-Lee D; Schmouder RL
    Int J Clin Pharmacol Ther; 2007 Feb; 45(2):98-109. PubMed ID: 17323789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects.
    Schmouder R; Serra D; Wang Y; Kovarik JM; DiMarco J; Hunt TL; Bastien MC
    J Clin Pharmacol; 2006 Aug; 46(8):895-904. PubMed ID: 16855074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose fingolimod (FTY720) in adolescents with stable renal transplants.
    Ettenger R; Schmouder R; Kovarik JM; Bastien MC; Hoyer PF
    Pediatr Transplant; 2011 Jun; 15(4):406-13. PubMed ID: 21585629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed cardiac dysrhythmias after fingolimod administration.
    Rosini JM; Rajasimhan S; Fellows SE; Nomura JT
    Am J Emerg Med; 2015 Jul; 33(7):987.e1-3. PubMed ID: 25669873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged and symptomatic bradycardia following a single dose of fingolimod.
    Faber H; Fischer HJ; Weber F
    Mult Scler; 2013 Jan; 19(1):126-8. PubMed ID: 22729989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers.
    Schmouder R; Hariry S; David OJ
    Eur J Clin Pharmacol; 2012 Apr; 68(4):355-62. PubMed ID: 22071882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel-group, phase I study in healthy subjects.
    Harada T; Wilbraham D; de La Borderie G; Inoue S; Bush J; Camm AJ
    Br J Clin Pharmacol; 2017 May; 83(5):1011-1027. PubMed ID: 27921320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deliberate fingolimod overdose presenting with delayed hypotension and bradycardia responsive to atropine.
    Stephenson M; Wong A; Rotella JA; Crump N; Kerr F; Greene SL
    J Med Toxicol; 2014 Jun; 10(2):215-8. PubMed ID: 24178903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The real-life experience with cardiovascular complications in the first dose of fingolimod for multiple sclerosis.
    Fragoso YD; Arruda CC; Arruda WO; Brooks JB; Damasceno A; Damasceno CA; Finkelsztejn A; Finkelsztejn J; Gama PD; Giacomo MC; Gomes S; Goncalves MV; Matta AP; de Morais MM; Oliveira EM; Ribeiro Y; Sato HK; Tauil CB
    Arq Neuropsiquiatr; 2014 Sep; 72(9):712-4. PubMed ID: 25252236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects.
    Kovarik JM; Schmouder R; Barilla D; Wang Y; Kraus G
    Br J Clin Pharmacol; 2004 May; 57(5):586-91. PubMed ID: 15089811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ketoconazole increases fingolimod blood levels in a drug interaction via CYP4F2 inhibition.
    Kovarik JM; Dole K; Riviere GJ; Pommier F; Maton S; Jin Y; Lasseter KC; Schmouder RL
    J Clin Pharmacol; 2009 Feb; 49(2):212-8. PubMed ID: 19118083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral fingolimod (FTY720) for relapsing multiple sclerosis.
    Kappos L; Antel J; Comi G; Montalban X; O'Connor P; Polman CH; Haas T; Korn AA; Karlsson G; Radue EW;
    N Engl J Med; 2006 Sep; 355(11):1124-40. PubMed ID: 16971719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of ceralifimod (ONO-4641) on lymphocytes and cardiac function: Randomized, double-blind, placebo-controlled trial with an open-label fingolimod arm.
    Krösser S; Wolna P; Fischer TZ; Boschert U; Stoltz R; Zhou M; Darpo B
    J Clin Pharmacol; 2015 Sep; 55(9):1051-60. PubMed ID: 25855155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
    N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fingolimod. Check cardiovascular status again on treatment resumption.
    Prescrire Int; 2014 Jan; 23(145):13. PubMed ID: 24516904
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.